Compare BRCB & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRCB | PRTC |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.9M | 386.7M |
| IPO Year | 2025 | N/A |
| Metric | BRCB | PRTC |
|---|---|---|
| Price | $21.95 | $16.64 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $28.40 | N/A |
| AVG Volume (30 Days) | ★ 521.3K | 1.8K |
| Earning Date | 02-08-2026 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $189,494,000.00 | $6,391,000.00 |
| Revenue This Year | $26.92 | N/A |
| Revenue Next Year | $27.11 | N/A |
| P/E Ratio | ★ N/A | $8.02 |
| Revenue Growth | 42.30 | ★ 1265.60 |
| 52 Week Low | $19.32 | $13.30 |
| 52 Week High | $30.40 | $20.00 |
| Indicator | BRCB | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.09 |
| Support Level | N/A | $16.72 |
| Resistance Level | N/A | $16.99 |
| Average True Range (ATR) | 0.00 | 0.40 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 30.88 |
Black Rock Coffee Bar Inc is a high-growth operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. It offers a broad range of premium coffee beverages, from its deliciously refreshing Nitro Cold Brew to its unapologetically indulgent Caramel Blondie. The company also offer competitively priced, premium classics, including the Americano and customizable Lattes, providing a high perceived value offering to its guests.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.